Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
VYROBIO logo — Developing next-generation viral immunotherapies to treat ag...

VYROBIO

Developing next-generation viral immunotherapies to treat aggressive, fast-growing forms of CNS tumors

Founded 2021 Brazil Brazil 9 employees Seed Total: $1.50M Biotechnology

General Information

Company Name VYROBIO
Founded Year 2021
Location Brazil Brazil
Employees 9
Industries Biotechnology
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with VYROBIO. To contact VYROBIO, visit vyrobio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does VYROBIO compare?

A PDF of VYROBIO and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting VYROBIO soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About VYROBIO

VYROBIO is a biotechnology startup based in Brazil that aims to revolutionize the treatment of malignant central nervous system (CNS) tumors. Founded in 2021, the company is focused on developing next-generation viral immunotherapies for aggressive, fast-growing forms of CNS tumors, both pediatric and adult. Their pioneering approach involves the utilization of oncolytic viruses (OVs) based on the properties of the Zika virus.

The latest milestone for VYROBIO was the successful securing of a $1.50M Seed Round investment from Vesper Ventures SA on 19 February 2022. This funding is expected to drive the further advancement of their innovative immunotherapy solutions.

Overall, VYROBIO presents an intriguing proposition in the biotechnology space, leveraging cutting-edge virology research to address a critical medical need. With their pioneering spirit and the backing of Vesper Ventures SA, VYROBIO is poised to make significant strides in the development of oncolytic immunotherapies for CNS tumors.

Business keywords: immuno-oncology, virotherapy, oncolytic virus, immunotherapy, cancer treatment, brain tumor, CNS tumors, pediatric oncology, Zika virus, viral immunotherapy, tumor-directed therapy, biotech startup, medical innovation, viral-based treatment

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $1.50M 1
Vesper Ventures SA
Vesper Ventures SA
19 Feb 2022

VYROBIO Alternatives & Competitors

View All Alternatives
VYROBIO vs
VacV Biotherapeutics
VacV Biotherapeutics United Kingdom

Developing oncolytic viruses as therapeutics for cancer

Seed
6 employees
Biotechnology, Health Care
VYROBIO vs
Turnstone Biologics
Turnstone Biologics United States

Developing next-generation TIL-based therapies to treat and cure solid tumors.

Series D
64 employees
Biotechnology, Health and Wellness
VYROBIO vs
OncoMyx Therapeutics
OncoMyx Therapeutics United States

We are developing myxoma virotherapies to expand the effectiveness of immunotherapies in the treatme...

Series B
8 employees
Biotechnology, Health Care
View all alternatives

FAQ About VYROBIO

Developing next-generation viral immunotherapies to treat aggressive, fast-growing forms of CNS tumors
VYROBIO was founded in 2021.
VYROBIO is headquartered in Brazil.
VYROBIO operates in Biotechnology. Its work centres on immuno-oncology, virotherapy, oncolytic virus and immunotherapy.
VYROBIO has approximately 9 employees.
VYROBIO has completed 1 funding round, raising a total of $1.50M. The latest funding stage is Seed.
Top alternatives and competitors to VYROBIO include VacV Biotherapeutics, Turnstone Biologics, OncoMyx Therapeutics, Vyriad, ViraTherapeutics GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VYROBIO and VacV Biotherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VYROBIO, https://bouncewatch.com/company/vyrobio, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout